细胞角蛋白19 mRNA在肾癌患者外周血中的表达

Detection of Cytokeratin 19 mRNA in Peripheral Blood by RT-PCR in Patients with Renal Cell Carcinoma

目的探讨细胞角蛋白19 mRNA在肾癌患者外周血中的表达及临床意义。方法利用逆转录多聚酶链反应检测26例肾癌患者和33例正常人外周血中细胞角蛋白19 mRNA的表达。结果26例肾癌患者中阳性表达19例,阳性表达率为73.1%,而33例正常人外周血中7例表达细胞角蛋白19 mRNA,阳性表达率为21.1%,肾癌组与正常对照组细胞角蛋白阳性表达差异具有统计学意义(P<0.01);其中Ⅰ期癌11例,阳性表达5例,阳性表达率为45.5%;Ⅱ期癌7例,阳性表达5例,阳性表达率为71.4%;Ⅲ期癌、Ⅳ期癌各4例,全部阳性表达(100%),Ⅰ期癌与Ⅱ、Ⅲ、Ⅳ期癌之间的阳性表达率差异有显著性(P<0.05)。结论细胞角蛋白19 mRNA的表达与肾癌的发生有关,可作为一个可早期诊断肾癌及其转移的生物学指标,并为肾癌患者提供更好的治疗方案。

Objective To investigate the expression and clinical significance of cytokeratin 19 （CK19） mRNA in periphexal blood in renal cell carcinoma patients. Methods CK19 mRNA in the peripheral blood of 26 patients with renal cell carcinoma and 33 healthy controls was amplified by reverse transcription-polymerase chain reaction （RT-PCR）. Results The positive detection rate was 73.1% （19/26） for renal cell carcinorma patients and 21.1% （7/33） for healthy controls. The number of patients expressing CK19 mRNA at each clinical stage was 5 out of 11（45.5% ） patients at stage Ⅰ ; 5 out of 7 （71.4%） at stage Ⅱ ; 4 out of 4 （100%） at stage Ⅲ; 4 out 4 （100%） at stage Ⅳ. A significant difference was seen between healthy controls and renal cell carcinomas by CK19 mRNA expression（ P 〈 0.01）, and also between different clinical stages （P〈0.05）. Conclusion CK19 mRNA may be a useful marker for early detection of renal cell carcinoma and its micrometastasis, and facilitate the design of better therapeutic strategies for the treatment of renal cell carcinoma patients.